The burden of diagnosed neuroendocrine tumors (NETs) is expected to increase at an annual growth rate (AGR) of 2.37% from an estimated 108,000 cases in 2020 to 133,000 in 2030 in the eight major markets (8MM*), according to GlobalData, a leading data and analytics company.
GlobalData’s latest report, ‘Neuroendocrine Tumors (NETs): Epidemiology Forecast to 2030’, reveals that the increase is attributed to the underlying demographic changes in the respective markets, and improvement in imaging tools used in diagnosis.
In the 8MM, China accounts for approximately 36% of all diagnosed incident cases due to its large population. In the five European markets (5EU), the UK accounts for …
Related posts:
It’s raining tech unicorns in India with increasing digital adoption, says GlobalData
Netherlands on track to phase out coal power by 2030, says GlobalData
New low-cost start-up Bonza Airlines set to fill void in Australia’s domestic routes, says GlobalDat...
Reduced risk of CV morbidity and mortality demonstrated in FIGARO-DKD study
